Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC

Autor:	Marika Rasschaert, Ranee Mehra, Katherine A. Scilla, Christian D. Rolfo, Hans Prenen, Patrick Pauwels, David Arias Ron, Alessandro Russo
Rok vydání:	2019
Předmět:	Pazopanib Cancer Research Oncology Refractory business.industry Fibroblast growth factor receptor 1 Cancer research Medicine Human medicine Personalized medicine Non small cell business medicine.drug
Zdroj:	JCO Precision Oncology
ISSN:	2473-4284
DOI:	10.1200/po.19.00243
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ade639477e108289df983bedcb8361e https://doi.org/10.1200/po.19.00243 Zobrazit plný text záznamu